Skip to search formSkip to main contentSkip to account menu

Extended interval dosing

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Serum Neurofilament Light (sNfL) Levels in Patients with Relapsing-remitting Multiple Sclerosis (RRMS) Switching from Natalizumab Every-4-week (Q4W) Dosing to Extended Interval Dosing (EID) (2013)
Objective: Evaluate sNfL levels in RRMS patients who switched from natalizumab Q4W dosing to EID compared to those who remained… 
2020
2020
Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: Updated analysis of the TOUCH…
Objective: Update the assessment of PML risk with natalizumab EID compared with Q4W dosing using TOUCH data as of June 1, 2019… 
2019
2019
Reduced risk of progressive multifocal leukoencephalopathy (PML) associated with natalizumab extended interval dosing (EID): updated analysis of the TOUCH® Prescribing Program database (S26.006)
Objective: To update the assessment of PML risk with natalizumab EID compared with standard interval dosing (SID) using TOUCH… 
2019
2019
Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the…
2018
2018
071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the…
Introduction Natalizumab, approved for 300 mg intravenous every-4-weeks dosing, is associated with PML risk. Prior studies have… 
2017
2017
Monitoring CD 49 d Receptor Occupancy : A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis patients Running Head : Monitoring and Optimizing Natalizumab Therapy
Background: In natalizumab-treated relapsing-remitting MS (RRMS) patients, various extended interval dosing strategies are under… 
2016
2016
Extended-interval gentamicin administration in neonates: an over-simplified approach
2016
2016
Response to “Extended-interval gentamicin administration in neonates: an over-simplified approach”
Response to “Extended-interval gentamicin administration in neonates: an over-simplified approach” 
2012
2012
Extended interval dosing of gentamicin in premature neonates ≤ 28‐week gestation
Aim:  To evaluate an extended interval dosing (EID) regimen of gentamicin in neonates ≤28‐week gestation. 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)